Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a227f4072f74cf78

Jump to content

Talk:Incyte

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 1 day ago by Mustbeotherwise in topic Updated "History" section

[Untitled]

[edit]
Latest comment: 5 years ago2 comments1 person in discussion

Basic financial information is out of date by several years, and can be verified easily with more current information. I am updating to the 2020 numbers https://www.nasdaq.com/market-activity/stocks/incy/financials DonInUtah (talk) 01:23, 27 July 2021 (UTC)Reply

Updated some of the company information and list of current drugs per verified information and SEC filings. I will look through other sections of the edit request to see that they are independently verified, meet wikipedia guidelines, and will include or exclude accordingly. DonInUtah (talk) 23:56, 26 July 2021 (UTC)Reply

Edit Request

[edit]

My name is Catalina Loveman and work for Incyte, a biotechnology company. In my role as Executive Director of Public Affairs, I manage all corporate communications efforts for the company. To be transparent, I will list my COIs, brands and any articles I work on below.

Company – Incyte

I am aware of Wikipedia's policies and guidelines, including those on WP:COI, WP:RS, WP:V and WP:NPOV, and I will abide by them. My edit suggestions will be restricted to Talk pages, and I will not engage in directly editing any articles related to the company/brands which I present, aside from correcting/reverting blatant misinformation or obvious vandalism.

On any pages where I may suggest changes, I will be sure to disclose relevant relationships in the interest of transparency on the Talk pages and state that I am not NPOV.

If you have any questions about my editing activities, please leave me a message on my User Talk page.

I would like to propose the following edits to the Incyte infobox:

  • Update financials to be current as of 2020: Net income (decrease) $US 149.85 million (2020); Total assets $US 3.56 billion (2020); Total equity $US 2.61 billion (2020) [1]
  • In “Number of employees,” reflect publicly-available figure: 1,600+[2]


I would like to propose the following edits to the introduction for accuracy:

  • Add a second sentence to reflect number of employees: It employs more than 1,600 employees. [3]
  • Update the following paragraphs in this section to more accurately describe Incyte medicines (i.e., the company has more than one drug): It receives royalties from three products – Jakavi® (ruxolitinib) ex-U.S., which is licensed to Novartis, and Olumiant® (baricitinib) and Tabrecta® (capmatinib) globally, which are licensed to Eli Lilly and Novartis, respectively. [4][5] The company is advancing a portfolio of medicines across Oncology and Inflammation & AutoImmunity. [6]


Finally, I would like to propose the addition of an external link: Incyte Corporate Website (www.incyte.com).

Please let me know if you have any feedback to these proposed changes.

References

  1. ↑ "Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Provides Updates on Key Clinical Programs". Incyte.com. Retrieved 2021-06-09.
  2. ↑ "Viewpoint: Delaware-born Incyte makes a global impact during crisis". Delaware Business Times. Retrieved 2021-06-09.
  3. ↑ "Viewpoint: Delaware-born Incyte makes a global impact during crisis". Delaware Business Times. Retrieved 2021-06-09.
  4. ↑ "Form 8-K, Incyte Corporation" (PDF). sec.gov. Retrieved 2021-06-09.
  5. ↑ "Our Leadership". Incyte.com. Retrieved 2021-06-09.
  6. ↑ "Our Leadership". Incyte.com. Retrieved 2021-06-09.

Details about founding?

[edit]
Latest comment: 3 years ago1 comment1 person in discussion

There seems to be something odd going on with the dates of founding. "The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware." First off, from the reference it looks like the merger actually officially took effect in 2003, it's just that Incyte lists 2002 as their founding date (https://www.incyte.com/who-we-are/biopharmaceutical-research). And it's also rather suspicious that they happened to have the same name as another company they're merging with.

To me it sure sounds like "Genomics" was a "shell" company specifically set up to take over "Pharmaceuticals" (and probably restructure their corporate structure.) - That is, it isn't really a "merger" of two independent companies, but rather it's a corporate restructuring which was framed as a merger for legalistic purposes. I'm not sure if Wikipedia readers are best served by the current phrasing, though since I'm lacking a bunch of the details and Incyte officially claim 2002 as their founding date I'm not sure how best to rephrase things. -- 129.59.122.107 (talk) 18:36, 13 February 2023 (UTC)Reply

Founder

[edit]
Latest comment: 9 months ago1 comment1 person in discussion

Why is the founder listed as George Washington in 1776? 100.19.9.122 (talk) 05:28, 29 September 2025 (UTC)Reply

Updated "History" section

[edit]
Latest comment: 1 day ago2 comments2 people in discussion

I'm Erik and I work at Incyte. I'm excited to collaborate with you all! Due to my conflict of interest, I am here with a request.

I'd like to request the wholesale replacement of the current History section on this article, with my proposed version. Half the citations in the current section are press releases or non-reliable sources, and the section itself doesn't really tell the story of Incyte's company history; it bounces from 2025 to 2015 to 2020 to 2021. The current section only really highlights two milestones in Incyte's history, and lacks a ton of context that is included in reliable sourcing. This proposed version tells that history more completely, while also improving the sourcing throughout.

Replace

In June 2025, Incyte named Bill Meury president, CEO, and a member of the board of directors. He replaced Hervé Hoppenot, who retired after 11 years of service.[1]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[2]
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[3] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[4]
Incyte established a European headquarters in Morges, Switzerland, in 2021.[5]

with this proposed content:

Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993.[1][2] Subsequently, scientists and chemists were recruited from DuPont to work for Incyte.[1][2] Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.[3][4][5]
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014.[6][7][8] Hervé Hoppenot became CEO in January 2014.[7]
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.[9]
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021.[10][11][12] The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022.[3] That same year, Incyte acquired Villaris Therapeutics, and Escient Pharmaceuticals in 2024.[13][14]
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income.[15][16] Incyte is publicly traded on the NASDAQ under the symbol INCY.[2] Incyte now operates out of North America, Asia, and Europe.[17] Bill Meury became CEO in 2025.[18] Meury replaced Hoppenot, who retired after 11 years in the position.[7][18]

References

  1. 1 2 Milford, Maureen (November 21, 2014). "Incyte takes over reimagined Wanamaker building". Delaware Online. Retrieved December 12, 2025.
  2. 1 2 3 "Incyte". Forbes Magazine. 2025. Retrieved December 17, 2025.
  3. 1 2 Owens, Jacob (April 4, 2022). "Incyte opens new R&D lab in Wilmington". Delaware Business Times. Retrieved December 12, 2025.
  4. ↑ Baker, Karl (August 5, 2020). "Incyte progresses on COVID-19 treatment. Other big Delaware companies slog through tough economy". Delaware Online. Retrieved December 12, 2025.
  5. ↑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION (2002). "QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934". SECURITIES AND EXCHANGE COMMISSION. Retrieved December 17, 2025.
  6. ↑ Malcolm, Wade (November 17, 2013). "Incyte to lease former Wanamaker building near Wilmington". Delaware Online. Retrieved December 12, 2025.
  7. 1 2 3 Anne Natoli, Cori (January 16, 2014). "Rising Incyte Corp. welcomes new CEO". Delaware Online. Retrieved December 12, 2025.
  8. ↑ Goss, Scott (March 3, 2015). "Incyte wins Delaware Bio company of the year honor, again". Delaware Online. Retrieved December 12, 2025.
  9. ↑ Mordock, Jeff (February 28, 2017). "Incyte joins prestigious Standard & Poor's 500 index". Delaware Online. Retrieved December 12, 2025.
  10. ↑ "Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
  11. ↑ "Prof. Jocelyne Bloch and Prof. Grégoire Courtine receive the BioAlps Academia Award, and Incyte the BioAlps Industry Award". Bio Alps. November 25, 2022. Retrieved May 4, 2026.
  12. ↑ Wilson, Xerxes (July 31, 2015). "Incyte considering 400 job expansion near Wilmington". Delaware Online. Retrieved May 4, 2026.
  13. ↑ George, John (October 3, 2022). "Incyte to acquire North Carolina drug developer in deal valued at up to $1.36 billion". Philadelphia Business Journal. Retrieved December 17, 2025.
  14. ↑ Tabeling, Katie (June 3, 2024). "Incyte closes $750M deal for Escient Pharmaceuticals". Delaware Business Times. Retrieved December 17, 2025.
  15. ↑ "Incyte Corp. 2025 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 10, 2026.
  16. ↑ Incyte (February 10, 2026). "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results". Incyte. Archived from the original on March 31, 2026. Retrieved March 31, 2026.
  17. ↑ Tabeling, Katie (October 23, 2024). "Incyte celebrated at du Pont Freedom Award reception". Delaware Business Times. Archived from the original on May 22, 2025. Retrieved December 17, 2025.
  18. 1 2 Tabeling, Katie (June 30, 2025). "Meury named Incyte CEO as Hoppenot departs". Delaware Business Times. Archived from the original on March 31, 2026. Retrieved March 31, 2026.

Let me know if anyone has questions here, and thanks INCY Erik (talk) 15:43, 8 June 2026 (UTC)Reply

Dear Erik, I have a couple suggestions
You suggest to add "The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022." I think it might be better to simply state research and development facility and omit major.
Also, you state "The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022. That same year, Incyte acquired Villaris Therapeutics, and Escient Pharmaceuticals in 2024." The inclusion of "that same year" is a bit confusing. Maybe exclude it?
Besides that, your article looks pretty good! Feel free to tag me once you address the issues, or alternatively, let me know if you disagree. Thanks! - Otherwise (Talk?) 16:10, 27 July 2026 (UTC)Reply
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Incyte&oldid=1366365108"